Cardiovascular Drugs and Therapy

, Volume 4, Supplement 5, pp 1005–1013 | Cite as

Excessive mural calcium overload — A predominant causal factor in the development of stenosing coronary plaques in humans

  • A. Fleckenstein
  • M. Frey
  • F. Thimm
  • G. Fleckenstein-Grün
Nifedipine and Atherogenesis

Summary

Healthy human coronary artery walls contain, over their entire lifetime, more free and total cholesterol than calcium. However, as soon as arteriosclerotic alterations set in, the calcium content increases. Thus in coronary fatty streaks (arteriosclerotic plaques of WHO stage I), calcium was increased 13 times, in stage II plaques 25 times, and in fully developed stage III plaques 80 times above normal on average. The most dramatic calcium incrustation was found in coronary stage III plaques that had produced massive fatal coronary infarction. Here, the proportion of calcium salts (particularly hydroxyapatite) may amount to almost 50% of dry weight. Thus the most excessive accumulation of calcium seems to be correlated with the highest fatality. In contrast, there is no correlation between mural coronary free or total cholesterol content, and plaque severity. Accordingly, stenosing coronary stage III plaques contain less cholesterol than do fatty streaks. Moreover, in coronary stage III plaques the proportion of free cholesterol was 1.37%, and of total cholesterol only 2.34% of the whole mass, certainly not enough for directly causing coronary occlusion. Thus the calcium-rich plaques of human coronary arteries considerably differ from the well-known cholesterol-rich plaques (stage I and II) of human aortae. Our findings justify a new prophylactic approach with suitable calcium antagonists, to interfere with deleterious calcium uptake in coronary plaque development.

Key Words

atherogenesis calcium overload coronary plaque tissue severity of plaques cholesterol accumulation antiarteriosclerotic effects of calcium antagonists 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity.J. Biol Chem. 1952;195:357–366.PubMedGoogle Scholar
  2. 2.
    Donike M, Schänzer W. Private communication (in press).Google Scholar
  3. 3.
    McGill HC Jr. Characterization of atherosclerotic lesions as they pertain to noninvasive, techniques. In: Hegyeli RJ, ed.Atherosclerosis reviews, vol. 10: Noninvasive methods in atherosclerosis research. New York: Raven Press, 1983:1–5.Google Scholar
  4. 4.
    Small DM. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. George Lyman Duff Memorial Lecture.Arterioslcerosis 1988;8:103–129.Google Scholar
  5. 5.
    Anitschkow N, Chalatow S. Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse.Zentralbl f Allgemeine Pathol u Anat 1913;14:1–9.Google Scholar
  6. 6.
    Katase A. Experimentelle Verkalkung am gesunden Tiere.Beiträge Path Anat und Allg Path 1913;57:516–550.Google Scholar
  7. 7.
    Herzenberg H. Studien über die Wirkungsweise des bestrahlten Ergosterins (Vigantol) und die Beziehungen der von ihm gesetzten Veränderungen zur Arteriosklerose.Beitr Path Anat, 1929;82:27–56.Google Scholar
  8. 8.
    Hass GM, Trueheart RE, Hemmens A. Experimental arteriosclerosis due to hypervitaminosis D.Am J Pathol 1960;37:521–539.PubMedGoogle Scholar
  9. 9.
    Eisenstein R, Zeruolis L. Vitamin-D-induced aortic calcification.Arch Pathol 1964;77:27–35.PubMedGoogle Scholar
  10. 10.
    Yogamundi Moon J. Factors affecting arterial calcification associated with atherosclerosis. A review.Atherosclerosis 1972;16:119–126.PubMedGoogle Scholar
  11. 11.
    Fleckenstein A, Kammermeier H, Döring HJ, et al.. Zum Wirkungsmechanismus neuatiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril.Z.f. Kreislaufforsch 1967;56:716–744, 839–858.Google Scholar
  12. 12.
    Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie L, eds.Calcium and the heart. Proceedings of the Meeting of the European Section of the International Study Group for Research in Cardiac Metabolism, London, September 1970. London: Academic Press, 1971:135–188.Google Scholar
  13. 13.
    Flekenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.Ann Rev Pharmacol. Toxicol 1977;17:149–166.CrossRefGoogle Scholar
  14. 14.
    Fleckenstein A.Calcium antagonism in heart and smooth muscle—experimental facts and therapeutic prospects. Monograph, New York: John Wiley, 1983.Google Scholar
  15. 15.
    Fleckenstein A. History of calcium antagonists. In: Schwartz A, Taira N, eds.Calcium channel blocking drugs: a novel intervention for the treatment of cardiac disease, Monograph No. 95 of the American Heart Association.Circ Res 52:1983;3–16.Google Scholar
  16. 16.
    Kohlhardt M, Bauer B, Krause H, Fleckenstein A. Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibers by the use of specific inhibitors.Pflügers Arch Physiol 1972;335:309–322.CrossRefGoogle Scholar
  17. 17.
    Fleckenstein A, Janke J, Döring HJ, Pachinger O. Ca overload as the determinant factor in the production of catecholamine-induced myocardial lesions. In: Bajusz E, Rona G, eds.Cardiomyopathies, Vol. 2, Recent advances in studies on cardiac structure and metabolism. Baltimore: University Park Press, 1973:455–466.Google Scholar
  18. 18.
    Fleckenstein A, Janke J, Döring HJ, Leder O. Myocardial fibre necrosis due to intracellular Ca overload—a new principle in cardiac pathophysiology. In: Dhalla NS, ed.Myocardial Biology. Vol. 4, Recent advances in studies on cardiac structure and metabolism. Baltimore: University Park Press, 1974:563–579.Google Scholar
  19. 19.
    Fleckenstein A, Janke J, Döring HJ, Leder O. The key role of Ca in the production of noncoronarogenic myocardial necroses. In: Fleckenstein A, Rona G, eds.Pathophysiology and morphology of myocardial cell alterations. Vol 6. Recent advances in studies on cardiac structure and metabolism. Baltimore: University Park Press, 1975:21–32.Google Scholar
  20. 20.
    Janke J, Hein B, Pachinger O. et al. Hemmung arteriosklerotischer Gefässprozesse durch prophylaktische Behandlung mit MgCl2, KCl und organischen Ca++-Antagonisten (quantitative Studien mit45Ca bei Ratten). In: Betz E ed.Vascular smooth muscle, verh satel symp XXV internat congr physiol wissenschaften, Tübingen, Juli 1971. Berlin: Springer Verlag, 1972:71–72.Google Scholar
  21. 21.
    Frey M, Keidel J, Flekenstein A. Verhütung experimenteller Gefässverkalkungen (Mönckeberg's Typ der Arteriosklerose) durch Calcium-Antagonisten bei Ratten In: Fleckenstein A, Roskamm H, eds.Calcium-antagonismus, Proceed Internat Symp in Frankfort, 1978. Berlin: Springer Verlag, 1980:258–264.Google Scholar
  22. 22.
    Fleckenstein A, Frey M, Fleckenstein-Grün G. Protection by calcium antagonists against experimental arterial calcinosis. In: Pyörälä K et al., eds.Secondary prevention of coronary heart disease. Workshop of the Internat. Soc. and Federation of Cardiology, Titisee, Oct 1983. Stuttgart: G. Thieme Verlag, 1983:109–122.Google Scholar
  23. 23.
    Fleckenstein A, Frey M, Leder O. Prevention by calcium antagonists of arterial calcinosis. In: Fleckenstein A et al., eds.Drug development and evaluation—New calcium antagonists—Recent developments and prospects. Diltiazem Workshop, Freiburg/Germany, May 1982. Stuttgart: Gustav Fischer Verlag, 1983:15–31.Google Scholar
  24. 24.
    Fleckenstein A, Frey M, v. Witzleben H. Vascular calcium overload—A pathogenetic factor in arteriosclerosis and its neutralization by calcium antagonists. In: Kaltenbach M, Neufeld HN, eds.New therapy of ischemic heart disease and hypertension. Proceed. of the 5th Internat. Adalat Symp. Berlin, May 1982, Amsterdam: Excerpta Medica, 1983:36–52.Google Scholar
  25. 25.
    Fleckenstein A, Frey M, Fleckenstein-Grün G. Antihypertensive and arterial anticalcinotic effects of calcium antagonists.Am J Cardiol 1986;57:1D-10D.CrossRefGoogle Scholar
  26. 26.
    Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists.Am J Cardiol 1985;56:3H-14H.CrossRefPubMedGoogle Scholar
  27. 27.
    Fleckenstein A, Fleckenstein-Grün G, Frey M, Zorn J. Future directions in the use of calcium antagonists.Am J Cardiol 1987;59:177B-187B.CrossRefPubMedGoogle Scholar
  28. 28.
    Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. The role of calcium in the pathogenesis of experimental arteriosclerosis.Trends Pharmacol Sci (TIPS) 1987;8:496–501.CrossRefGoogle Scholar
  29. 29.
    Fleckenstein A. Model experiments on anticalcinotic and antiarteriosclerotic arterial protection with calcium antagonists.J Mol Cell Cardiol 1987:19(Suppl II):109–121.PubMedGoogle Scholar
  30. 30.
    Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G, Calcium, a neglected key factor in hypertension and arteriosclerosis. Experimental vasoprotection with calcium antagonists or ACE inhibitors. In: Laragh JH, Brenner BM eds.Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press, 1990:471–509.Google Scholar
  31. 31.
    Lichtlen P. Antisclerotic effects of nifedipine: The INTACT-study. In:New trends, aspects, and long-term benefits of calcium antagonists-Focus on Adalat. Proceedings of a Symposium in Vancouver, April 1989.Cardiovasc Drugs Ther Boston: Kluwer Academic Publishers, in press.Google Scholar
  32. 32.
    Kober G, Schneider W, Kaltenbach M. Can the progression of coronary sclerosis be influenced by calcium antagonists?J Cardiovasc Pharmacol 1989;13:S2-S6.PubMedGoogle Scholar
  33. 33.
    Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists.Am J Cardiol 1987;59:163B-172B.CrossRefPubMedGoogle Scholar
  34. 34.
    Weinstein DB. Protective effects of calcium channel antagonists in experimental models of atherogenesis and vascular disease. In: Laragh JH, Brenner BM, eds.Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press, 1990:511–519.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • A. Fleckenstein
    • 1
  • M. Frey
    • 1
  • F. Thimm
    • 1
  • G. Fleckenstein-Grün
    • 1
  1. 1.Study Group for Calcium Antagonism Physiological Institute of the University of FreiburgFreiburgFRG

Personalised recommendations